GlassScriptPhysician profile
Boris Avezbakiyev
NPI 1396794921
$10,864.85
in general payments reported to CMS, 2019-2025
55 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,925 · 2020: $1,540 · 2021: $1,511 · 2022: $1,698 · 2023: $1,952 · 2024: $1,066 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,952 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,952.04 |
| Education | $238.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,291.35 | 2019-2024 | Opdivo, Eliquis, Augtyro |
| Pfizer INC. | $890.39 | 2019-2025 | |
| Janssen Biotech, INC. | $742.43 | 2019-2024 | Darzalex, Tecvayli, Imbruvica |
| Amgen INC. | $681.25 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Astellas Pharma US INC | $657.75 | 2019-2024 | Xtandi, Padcev |
| Astrazeneca Pharmaceuticals LP | $577.83 | 2019-2024 | Tagrisso, Andexxa, Lynparza |
| Merck Sharp & Dohme LLC | $564.48 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Genzyme Corporation | $528.57 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $478.73 | 2019-2022 | |
| Seagen INC. | $446.85 | 2019-2023 | Adcetris, Padcev |
| Novartis Pharmaceuticals Corporation | $354.83 | 2019-2024 | |
| Emd Serono, INC. | $347.44 | 2019-2023 | Tepmetko |
| Octapharma USA, INC. | $246.46 | 2021-2025 | Panzyga, Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human), Fibryga |
| Lilly USA, LLC | $238.08 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $186.86 | 2023-2024 | Ultomiris |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Avezbakiyev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.